AVVie GmbH (‘Angel Valve’) achieved important milestone completing 90 days chronic animal trial for their Mitral Butterfly design.

Mitral Butterfly is a proprietary chordal repair technique restoring the coaptation plane of a flail leaflet in degenerative mitral regurgitation. Additionally, the unique deployment technique restores the support apparatus of the mitral valve in one step. It is an unparalleled technique and a differentiated method from presently known repair concepts. The primary advantage of the mechanism of action containing the prolapsing segment is the introduction of an artificial papillary muscle as valvular support.
The Mitral Butterfly device is intended to advance chordal repair. The present chronic animal study was to demonstrate safety of the device at 90-day follow-up. There were no device related adverse effects and no deterioration of valve function during follow up. All safety endpoints were met, and structural integrity was maintained out to an average of 12 million cycles per animal.
Patrick Maguire MD, MBA, said: “the successful completion of the chronic animal study is a major step in the development of a feasible mitral repair system and an advancement of mitral innovation”. Werner Mohl, MD, PhD, Founder of AVVie added: “we are pleased to reach this important milestone in line with our ambitious development plan. We are committed to bring a safe and effective device to the clinical arena.